Who is running the show in regard to development of tivantinib and the trials?
Is it ARQL or is it Daiichi? If it's ARQL, the Board should fire the CEO because there have just been way too many stupid mistakes which cost significant time and money (yes, it is the CEOs fault, can't blame the scientists....unless, of course, the drug isn't even a c-met, but some sort of inhibitor that just happens to hit Met in some respect).
If it's Daiichi....well, Daiichi is a cardio company with little if any experience in oncology development except for their recent buy-in of the space with Plexxikon. So, their development of oncology products is pretty much at zero, so to speak. Awful partner choice by Arqule, but, then again, maybe it was their ONLY choice.
Maybe they'll just get lucky one of these times...
